Since our evidence suggests that SOX2 activates AKT survival signaling and promotes spheroid-forming ability by inducing IGF2/IGF1R in bladder cancer cells, IGF2 and IGF1R may be potential therapeutic targets for treating bladder cancer. Here, IGF1R is linked to urinary bladder cancer.